Emilia Gabriela Sardo2026-03-27T14:38:22+01:00

Emilia Gabriela Sardo

Member of the Cancer Profiling Research Line

Email: emiliagabriela.sardo@uvic.cat

ORCID: 0000-0002-1764-0528

Scientific Profile: URECERCA

I am a Medical Oncologist who graduated in Medicine from the Universidad Católica de Córdoba. After completing my residency training, I pursued a fellowship at the Hospital Universitario Vall d’Hebron and subsequently undertook an observership at the Università degli Studi della Campania Luigi Vanvitelli in Naples, Italy.

I currently work as a Consultant Medical Oncologist at the Hospital Universitari de Vic, where I am involved in clinical work and clinical research, alongside teaching activities. My clinical practice focuses on breast cancer and gynaecological cancers, allowing me to integrate patient care with research in a direct and meaningful way. I am actively involved in the training of medical residents and in undergraduate teaching at the Universitat de Vic – Central University of Catalonia, where I serve as Associate Professor of Oncology.

Since September 2022, I am pursuing a PhD in Medicine and Biomedical Sciences at the Universitat de Vic – Central University of Catalonia, supported by an Industrial Doctorate fellowship. My research focuses on translational research in gynaecological cancers, with a particular emphasis on endometrial cancer. In parallel, I am also enrolled in a postgraduate Expert Programme in gynaecological cancers at the Universitat de Girona, further strengthening my specialised training in this field.

My last happenings:

Adult-specific Reelin expression alters striatal neuronal organization: implications for neuropsychiatric disorders

Autors: Pardo M, Gregorio S, Montalban E, Pujadas L, Elias-Tersa A, Masachs N, Vílchez-Acosta A, Parent A, Auladell C, Girault JA, Vila M, Nairn AC, Manso Y, Soriano E. Front Cell Neurosci. 2023 Apr 20;17:1143319 doi: 10.3389/fncel.2023.1143319 Read More Abstract: In addition to neuronal migration, brain development, and adult plasticity, the extracellular matrix protein Reelin has been extensively implicated in human psychiatric disorders such as schizophrenia, bipolar disorder, and autism spectrum disorder. Moreover, heterozygous reeler mice exhibit features reminiscent of these disorders, while overexpression of Reelin protects against its manifestation. However, how Reelin influences the structure and circuits of the [...]

March 16, 2026|

A key amino acid site associated with rhodopsin mammal evolution to diurnal vision.

Authors: Fernández-Sampedro MA, Ramon E, Aguileta G, Bosch-Presegué L, Garriga P. Sci Rep. 2025 Dec 26;16(1):411 doi:10.1038/s41598-025-29872-9. Read More Abstract Rhodopsin is a photoreceptor protein found in the vertebrate retina used as a landmark for vision evolution studies at the molecular level. Here, we examined the biochemical and functional performance of modern rhodopsin from three different mammal species- bovine, murine and human-to analyze their visual pigment evolutionary relationships. We selected these species for their relevance in vision research, their different position on the phylogenetic tree and their diverse ethology regarding nocturnal (mouse) and diurnal (bovine and human) life. [...]

February 23, 2026|

The diagnostic accuracy of HE4 in the differential diagnosis of pleural effusions.

Authors: Bérgamo S, Trapé J, González-García L, González-Fernández C, Vergara C, la-Torre ND, Bosch-Presegué L, Otero-Viñas M, Catot S, Crespo-Casal M, Rives-Jimenez J, Arnau A, Costa R, Cugat JR, Gonzalez-Sánchez F, Pla-Salas X, Sant F. Clin Chim Acta. 2025 Jan 30;566:120027. doi:10.1016/j.cca.2024.120027 Read More Abstract Background: Pleural effusions are challenging to diagnose, with approximately 20-50% of malignant effusions not diagnosed by cytology. Human epididymal protein 4 (HE4) may be useful in the differential diagnosis of pleural effusions. In serum, this biomarker shows false-positive results in some benign diseases. The aim of this study was to evaluate the diagnostic utility [...]

February 23, 2026|
Go to Top